Introduction {#cesec10}
============

Advanced colorectal cancer is the second most common cause of death from cancer in developed countries, after lung cancer.[@bib1; @bib2] In the UK, the median age at death from advanced colorectal cancer is 77 years, with 60% of deaths occurring in patients older than 75 years and 42% in those older than 80 years.[@bib3] Frailty, whether or not related to the cancer diagnosis, is frequent in elderly patients.

Standard treatment for advanced colorectal cancer includes palliative chemotherapy, with an expanding range of treatment options. But the evidence supporting these treatments is from clinical trials that under-represented elderly, frail, and especially frail elderly patients.[@bib4] Several pivotal trials were restricted to patients younger than 75 years;[@bib5; @bib6; @bib7] however, even without a formal upper age limit there are several impediments to the recruitment of elderly participants.[@bib8] Reports of outcomes in older[@bib4] or frailer[@bib9] patient subsets within these trials, although interesting, are limited by the fact that the participants were by definition sufficiently robust to have been included in the trials in the first place, whereas many other patients were not.

In 2002, the UK Medical Research Council (MRC) noted that investigators of its first-line trial for advanced colorectal cancer, FOCUS (Fluorouracil, Oxaliplatin, CPT11 \[irinotecan\]: Use and Sequencing),[@bib10] despite permissive entry criteria and no upper age limit, were recruiting patients with a median age of only 64 years. A survey of investigators showed that the 59 trial oncologists who responded, while recruiting 422 patients into FOCUS, had treated a further 715 patients off-trial during the same period, frequently using reduced-dose or single-agent schedules. The most common reasons cited for non-inclusion of technically eligible patients were physicians\' concerns about the adverse effects of standard-dose treatments, patients\' wishes to avoid toxic effects, and an assumption that oral therapy would improve quality of life (QoL). We therefore designed FOCUS2 for patients with advanced colorectal cancer who were to receive chemotherapy, but for whom the treating oncologist considered standard full-dose regimens to be unsuitable.

Methods {#cesec20}
=======

Study design and patients {#cesec30}
-------------------------

Three trial design innovations were used to make FOCUS2 suitable for the frail and elderly population to be studied. First, as is common in non-trial practice, cytotoxic drugs were started at below-standard doses; second, a comprehensive geriatric health assessment was used to identify factors that might aid future selection of patients or regimens; third, alongside standard outcome measures a composite measure of overall treatment utility (OTU) was devised, incorporating objective and subjective measures of benefit and harm.

FOCUS2 was undertaken in 61 UK centres, recruiting patients between January, 2004, and July, 2006. To enter FOCUS2, the oncologist had first to confirm, stating reasons, that the patient was in his or her opinion not a candidate for standard full-dose combination therapy. Patients had to have histologically confirmed colorectal adenocarcinoma, with unidimensionally measurable inoperable advanced or metastatic disease, and a WHO performance status of 2 or better. Patients had to have received no previous systemic chemotherapy for metastases. There was no upper or lower age limit. Previous adjuvant chemotherapy was allowed if completed more than 4 months before randomisation; previous rectal chemoradiotherapy was allowed if completed more than 1 month before randomisation. Patients were not excluded for medical comorbidity unless the condition was so severe as to preclude protocol treatment. However, the following criteria were required: white blood cell count 3×10^9^ per L or greater, platelet count 100×10^9^ per L or greater, serum bilirubin no more than three times the upper limit of normal (ULN), serum transaminases no more than 2·5 times ULN, and glomerular filtration rate (GFR) 30 mL per min or greater.

We obtained written consent after verbal explanation and a written information sheet had been given to the patient, with at least 24 h allowed for consideration. Thereafter, but before randomisation, a 117-item comprehensive health assessment (CHA) was done ([webappendix pp 1--8](#sec1){ref-type="sec"}). This assessment comprised four nurse-administered modules (physical parameters including timed 20-m walk,[@bib11] mini-nutritional assessment,[@bib12] mini-mental state examination,[@bib13] and medical comorbidity[@bib14]) and four patient-completed modules (activities of daily living,[@bib15] symptoms,[@bib16] anxiety or depression,[@bib17] and global QoL or health resources[@bib18]).

FOCUS-2 was approved by national and institutional research ethics committees and undertaken by the MRC Clinical Trials Unit (CTU), with MRC Good Clinical Research Practice,[@bib19] and was overseen by an independent Trial Steering Committee. Confidential interim analyses were reviewed every year by an independent Data Monitoring Committee.

Randomisation and masking {#cesec40}
-------------------------

Patients were randomly assigned in a 1:1:1:1 ratio by telephone with a computerised algorithm developed and maintained centrally at the MRC CTU. Randomisation was done by use of the method of minimisation stratified by clinician, WHO performance status, status of primary tumour (resected or not), and age. Treatment allocation was not masked.

Procedures {#cesec50}
----------

Treatment was started with standard regimens but at 80% of standard cytotoxic drug doses. Group A received levofolinate 175 mg 2-h intravenous infusion, fluorouracil 320 mg/m^2^ 5-min intravenous bolus, and fluorouracil 2240 mg/m^2^ 46-h intravenous infusion. The cycle was repeated every 14 days (FU regimen). This regimen is 80% of the simplified LV5FU2 regimen used in FOCUS.[@bib10; @bib20] Group B received levofolinate 175 mg/m^2^ and oxaliplatin 68 mg/m^2^ by concurrent 2-h intravenous infusion, fluorouracil 320 mg/m^2^ 5-min intravenous bolus, and fluorouracil 1920 mg/m^2^ 46-h intravenous infusion. The cycle was repeated every 14 days (OxFU regimen). This regimen is 80% of the simplified FOLFOX regimen in FOCUS.[@bib10; @bib20] Group C received capecitabine 1000 mg/m^2^ orally twice per day on days 1--15. The cycle was repeated every 21 days (Cap regimen). This regimen is 80% of the standard licensed schedule. Group D received oxaliplatin 104 mg/m^2^ 2-h intravenous infusion, and capecitabine 800mg/m^2^ orally twice per day on days 1--15. The cycle was repeated every 21 days (OxCap regimen). This regimen is 80% of the standard XELOX regimen.[@bib21] In patients with GFR 30--50 mL per min, oxaliplatin and capecitabine were further reduced by 25%.

Before each cycle, toxicity was scored with common terminology criteria for adverse events (version 3.0). Detailed management of side-effects was specified; briefly, grade 1 and worse effects were treated symptomatically; persisting grade 2 and worse toxicity at day 1 of the next treatment cycle incurred a 1-week delay. Cytotoxic doses were reduced by 20% after two delays, or one delay of 2 weeks or more. If grade 2 or worse transaminitis (\>2·5 times ULN) developed during capecitabine therapy, treatment was held until recovery. For grade 3 hyperbilirubinaemia (\>3 times ULN), all cytotoxic drugs were reduced by 50%. Oxaliplatin was omitted for persistent grade 2 and worse neurological toxic effects. Compliance with capecitabine was assessed with patient diary cards and tablet returns.

A senior clinician assessment was scheduled after 6 weeks, when doses could be escalated to 100% of standard doses (an increase of 25% of starting doses), provided that no grade 2 or worse non-haematological toxic effects had occurred and that the patient assented. After week 12, radiological response was assessed with Response Evaluation Criteria In Solid Tumors (RECIST) criteria;[@bib22] the clinician assessed whether there had been clinical deterioration in the patient; the CHA was repeated (omitting the comorbidity and mental-state modules) and the patient was asked two additional questions: whether their treatment had been worthwhile and how much it had interfered with activities ([webappendix pp 9--13](#sec1){ref-type="sec"}).

Thereafter, patients without radiological or clinical evidence of deterioration could continue the same regimen, immediately or after a planned break, with reassessment every 12 weeks. In groups A and C, when progression occurred on the FU or Cap regimens, second-line treatment was considered with the OxFU or OxCap regimens, respectively. Second-line therapy in groups B and D, and third-line therapy in all groups, was at the discretion of the physician.

Statistical analysis {#cesec60}
--------------------

The primary questions in the two factorial comparisons were: does oxaliplatin improve first-line progression-free survival (PFS; \[A *vs* B\] + \[C *vs* D\])?; and does substitution of fluorouracil with capecitabine improve global QoL (\[A *vs* C\] + \[B *vs* D\])?

For the first question, PFS was defined as time from randomisation to first progression or death from any cause, assessed by intention to treat. FOCUS2 was designed to detect a 3-month improvement in median PFS from 6 months to 9 months. For 90% power at the two-sided 5% significance level, 460 patients were needed.

For the second question, the primary outcome was QoL improvement. This outcome was defined as any increase between baseline and 12 weeks in the EORTC-QLQ-C30 global QoL subscale, reported as a percentage of patients with baseline and 12-week data. In a previous MRC trial,[@bib23] 40% of 117 patients reported improved global QoL with this criterion. Paired data from 260 patients (57% of the total) would be sufficient to detect an increase from 40% to 60%, at the two-sided 5% significance level, with 90% power. PFS was a secondary outcome for this comparison.

Secondary outcome measures for both comparisons included response rate (RR), toxic effects, and overall survival (OS). For time-to-event endpoints, Kaplan-Meier curves were produced with patients alive and event-free being censored at the time last seen. Hazard ratios (HRs) and 95% CIs were calculated for each comparison and compared with stratified log-rank tests. RR and toxic effects are reported as percentage of assessable patients and compared with χ^2^ tests. We compared QoL improvement with the Mann-Whitney test, which allows for non-normality. Tests for heterogeneity were done for time-to-event outcomes and tests of interaction for all other outcomes.

The novel composite measure OTU was devised to reflect whether, from the viewpoint of both patient and clinician and with use of both objective and subjective measures, the treatment had been worthwhile. OTU was scored at 12 weeks ([webappendix p 14](#sec1){ref-type="sec"}). Briefly, good OTU indicated no clinical or radiological evidence of disease progression, and no major negative treatment effects in terms of toxicity or patient acceptability. Intermediate OTU signified either clinical deterioration but no negative treatment effect, or a significant negative treatment effect but no clinical deterioration. Poor OTU indicated both clinical deterioration and a major negative treatment effect, or death.

We then investigated whether baseline clinicopathological and CHA data can help to predict the probability of a favourable OTU at 12 weeks. Categorical factors and continuous factors with predefined cutoffs for categories were treated as categorical, with all other variables regarded as continuous. Univariate analyses were first done, with ordinal logistic regression, to assess patients\' baseline characteristics and CHA data in relation to the OTU score at 12 weeks. All variables, irrespective of their univariate result, were then included in a multivariable analysis with backward stepwise ordinal logistic regression. Results are displayed with odds ratios (ORs) to show the odds of a worse outcome, with effect size (*Z* value) and statistical significance (p value).

This study is registered, number ISRCTN21221452.

Role of the funding source {#cesec70}
--------------------------

The sponsor of the study was the MRC which, as the parent body of the MRC CTU, was involved in the design, conduct, and analysis of the trial. The manufacturers of the drugs used in the study were not involved in the research. The corresponding author had full access to the data and had final responsibility for the decision to submit for publication.

Results {#cesec80}
=======

[Figure 1](#fig1){ref-type="fig"} shows the trial profile. 411 of 459 (90%) patients had died at the time of final analysis. Baseline characteristics were well balanced between groups ([table 1](#tbl1){ref-type="table"}). Median age was 74 years (range 35--87), with 199 (43%) patients older than 75 years and 60 (13%) older than 80 years. 98 (21%) patients had WHO performance status of 0, 227 (49%) a performance status of 1, and 134 (29%) a performance status of 2. The reason for inclusion in FOCUS2 instead of a full-dose protocol was cited as frailty in 324 (71%) patients and advanced age in 311 (68%). However, dementia was uncommon: full baseline mini-mental health data were obtained in 387 patients, of whom 374 (96%) scored within the normal range and only two (0·5%) fell within the range associated with dementia.

419 (91%) patients were alive and receiving treatment 6 weeks after starting treatment, and so were eligible for discretionary escalation to 100% of standard doses ([table 2](#tbl2){ref-type="table"}). Of these patients, 154 (37%) had dose escalation. Dose escalation was more frequent in patients allocated single agent than combination therapy (p=0·01). Only 60 (14% of all patients starting treatment) sustained the higher dose to 12 weeks ([table 2](#tbl2){ref-type="table"}). 146 (33%) patients sustained the 80% standard starting dose to 12 weeks, whereas 215 (49%) needed a further dose reduction or stopped ([table 2](#tbl2){ref-type="table"}). Capecitabine compliance, assessed by tablet returns, was greater than 97% in the Cap (group C) and OxCap (group D) regimens (data not shown).

At the time of analysis 445 (97%) patients had had a PFS event ([figure 2A](#fig2){ref-type="fig"}). PFS, measured by intention to treat, was the primary outcome measure for the factorial comparison of treatment with or without oxaliplatin; this comparison suggested some benefit of oxaliplatin but the finding was not significant ([figure 2A](#fig2){ref-type="fig"}; [table 3](#tbl3){ref-type="table"}). Factorial comparison of fluorouracil versus capecitabine showed no effect on PFS ([figure 2B](#fig2){ref-type="fig"}; [table 3](#tbl3){ref-type="table"}).

Paired baseline and 12-week QoL data were available in 247 patients, with similar numbers in each group ([table 3](#tbl3){ref-type="table"}). QoL improvement was the primary outcome measure for the factorial comparison of fluorouracil versus capecitabine; this comparison showed no difference between groups, with more than half of assessable patients reporting improved QoL in both groups ([table 3](#tbl3){ref-type="table"}). Factorial comparison of treatment with and without oxaliplatin was suggestive of a detrimental effect with oxaliplatin regimens ([table 3](#tbl3){ref-type="table"}).

RR was assessed with RECIST criteria but only at 12 weeks after randomisation. In the factorial comparisons, we recorded good evidence that oxaliplatin increased the RR (complete response plus partial response) and the rate of disease control (stable disease, complete response, and partial response; [table 3](#tbl3){ref-type="table"}). We noted no evidence that the substitution of fluorouracil with capecitabine had an effect on response or disease control ([table 3](#tbl3){ref-type="table"}).

Factorial analysis showed no evidence of OS benefit with first-line oxaliplatin ([figure 2C](#fig2){ref-type="fig"}). Similarly, factorial analysis showed no difference in OS between fluorouracil and capecitabine ([figure 2D](#fig2){ref-type="fig"}).

440 (96%) patients had complete data for toxic effects. The overall risk of having a grade 3 or worse event during the first 12 weeks ranged from 27% of assessed patients (29 of 109) with the FU regimen to 43% (47 of 110) with the OxCap regimen ([table 4](#tbl4){ref-type="table"}). In the factorial comparisons, the use of oxaliplatin did not significantly increase the overall risk of toxic effects, but we noted evidence of increased rates of diarrhoea, neurosensory toxicity, nausea, vomiting, and neutropenia, and a lower rate of hand-foot syndrome compared with no use of oxaliplatin ([table 4](#tbl4){ref-type="table"}). Compared with fluorouracil, capecitabine increased the overall risk of a grade 3 or worse event (p=0·03), and was specifically associated with increased rates of nausea, vomiting, diarrhoea, anorexia, and hand-foot syndrome.

438 (95%) patients had complete data to allow scoring of OTU at 12 weeks, of whom 182 (42%) scored good, 140 (32%) intermediate, and 116 (26%) poor. Better OTU was strongly associated with improved PFS and OS (both p\<0·0001, log-rank trend test; data not shown). In the factorial comparisons, allocation to receive oxaliplatin was associated with better OTU (p=0·003), but we recorded no significant difference in OTU with fluorouracil or capecitabine ([table 3](#tbl3){ref-type="table"}).

Univariate analysis was done with baseline clinicopathological variables, CHA variables, and treatment allocation ([figure 3](#fig3){ref-type="fig"}). The strongest predictors of 12-week OTU were: WHO performance status, white blood cell count, EQ5D QoL score, overall symptom score, and allocation to oxaliplatin (all p\<0·01; [figure 3](#fig3){ref-type="fig"}). We recorded no evidence of interaction between the two treatment factors (p=0·209; data not shown).

Multivariable analyses ([table 5](#tbl5){ref-type="table"}) produced a potentially predictive model based on overall symptom score, presence of liver plus extrahepatic metastases, and treatment. WHO performance status and age were included for clinical relevance. On the basis of this model, a 70-year-old patient with performance status of 1, with both liver and extrahepatic metastases, whose overall symptom score is 60, treated with single-agent fluoropyrimidines, has a 61% (95% CI 45--76) probability of a poor OTU and only a 12% (5--20) probability of a good OTU. Conversely, an 80-year-old patient with performance status of 1 and a symptom score 0 and either extrahepatic-only or liver-only disease, treated with combination chemotherapy, has a 66% (56--77) probability of a good OTU and only 10% (5--14) probability of a poor OTU.

Discussion {#cesec90}
==========

This is the largest randomised controlled trial so far to have selectively recruited frail and elderly patients with advanced colorectal cancer ([panel](#box1){ref-type="boxed-text"}). With use of reduced starting drug doses, adapted for this population, combination chemotherapy including oxaliplatin seems, on balance, preferable to single-agent fluoropyrimidines, although the primary endpoint of PFS was not met. We did not, however, detect any advantage of capecitabine compared with fluorouracil.

FOCUS2 successfully recruited an elderly and frail population into a large national trial. Indeed, the trial proved so popular with patients and clinicians that it recruited well ahead of target, showing that age and frailty need not be barriers to research. The decision to start treatments at 80% of standard doses, although arbitrary, mimics common non-trial practice in frail elderly patients. Generally moderate rates of toxic effects and good rates of improvement in QoL in all groups would seem to support this strategy, whereas the relatively low uptake of escalation at 6 weeks, and the fact that only 14% of all patients sustained full-dose therapy to 12 weeks, supports the notion that the trial population was unsuited for full-dose therapy.

We introduced a novel composite endpoint, OTU, to assess the outcome of palliative chemotherapy, and explored the use of objective baseline evaluation to estimate the likelihood of a good or poor outcome with treatment. When confirmed and refined with further studies, this approach could potentially provide valuable guidance for doctors and patients in the difficult decisions between active or symptomatic care or, potentially, between active regimens. The interpretation of clinical trials, especially trials of palliative chemotherapy, often needs subjective synthesis of the objective data. Measures of efficacy are weighed against toxic effects, convenience, and other variables before deciding which treatment is best. For FOCUS2 we developed a simple composite endpoint of treatment outcome, OTU, to reflect both the doctor\'s question: "In retrospect, am I glad I offered this treatment?"; and the patient\'s question: "Am I glad I accepted it?". OTU combines clinical efficacy ("Is my patient alive without disease progression?"), clinical tolerability ("Did we avoid causing major harm?"), and patient opinion ("Was my treatment worthwhile and acceptable?"). We encourage other research groups to adopt and refine this patient-centred approach.

OTU proved useful in comparison of treatment groups, particularly when conventional endpoints were divergent. The addition of oxaliplatin significantly increased RR and suggested some improvement in PFS, although this finding was not significant; however, it also increased some toxic effects and seemed to negatively affect global QoL. So overall, was treatment with oxaliplatin worthwhile? OTU showed unequivocal evidence of overall benefit with oxaliplatin ([table 3](#tbl3){ref-type="table"}; [figure 3](#fig3){ref-type="fig"}).

For the second factorial question, capecitabine has previously been shown to be non-inferior to fluorouracil,[@bib28] and oral therapy is generally thought to be preferred by patients, either because of its convenience or because it is assumed to have low toxicity. However, although analysis of PFS and RR confirmed capecitabine\'s efficacy, we recorded increased toxicity and no evidence of improved QoL. And despite including a measure of whether treatment interferes with patients\' normal activities, the OTU scores for patients receiving capecitabine were not superior; indeed, they tended to favour fluorouracil, although this difference was not significant ([table 2B](#tbl2){ref-type="table"}; [figure 3A](#fig3){ref-type="fig"}).

Guidelines from the US National Comprehensive Cancer Network recommend use of a comprehensive geriatric assessment (CGA) to guide decision making when considering chemotherapy in elderly patients.[@bib29; @bib30] However, there currently exists no evidence-based method to combine the many data items generated by the CGA into one decision about whether to offer chemotherapy, or which regimen to use. The 117-item geriatric assessment used in FOCUS2 was feasible in the oncology clinic, and we have started to identify which elements are of greatest value in prediction of the use of palliative chemotherapy. To develop a working predictive model will need cross-validation with other studies, but this approach offers the potential to better inform oncologists\' discussions with patients. For example, a high predicted probability of a good OTU would support encouragement for chemotherapy; conversely, a high predicted probability of poor OTU (eg, in a patient with a high symptom score and widespread metastases) might help the oncologist and patient to consider with confidence the option of non-chemotherapy-based care.

New therapies now present new opportunities to develop treatments with few toxic effects for frail elderly patients with advanced colorectal cancer. For example, investigators of the AGITG MAX trial,[@bib31] undertaken in patients of median age 68 years, reported significantly improved PFS without significant extra toxicity from the addition of bevacizumab to single-agent capecitabine. We encourage investigators to continue to design trials using appropriate low-toxicity treatments and patient-centred assessment to expand the evidence base in this important specialty.

Web Extra Material {#sec1}
==================
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![Trial profile\
FU=simplified LV5FU2 regimen of levofolinate, bolus fluorouracil, and 46-h infusion of fluorouracil, repeated every 2 weeks. OxFU=oxaliplatin plus FU. Cap=capecitabine. OxCap=oxaliplatin plus Cap. OxFp=oxaliplatin plus fluoropyrimidine (either fluorouracil or capecitabine).](gr1){#fig1}

![Kaplan-Meier curves for PFS and OS for each main effect comparison and hazard ratio plots to show tests for heterogeneity for each factorial comparison\
(A) PFS by addition of oxaliplatin. (B) PFS by FU versus Cap. (C) OS by addition of oxaliplatin. (D) OS by FU versus Cap. PFS=progression-free survival. OS=overall survival. FU=simplified LV5FU2 regimen of levofolinate, bolus fluorouracil, and 46-h infusion of fluorouracil, repeated every 2 weeks. OxFU=oxaliplatin plus FU. Cap=capecitabine. OxCap=oxaliplatin plus Cap.](gr2){#fig2}

![Association of categorical factors (A) and continuous factors (B) associated with OTU outcome\
Odds of a worse outcome is expressed with reference to the more normal state, or as an odds ratio proportional across all categories. OTU=overall treatment utility. WBC=white blood cell. GFR=glomerular filtration rate. BMI=body-mass index. FU=simplified LV5FU2 regimen of levofolinate, bolus fluorouracil, and 46-h infusion of fluorouracil, repeated every 2 weeks. Ox=oxaliplatin. Cap=capecitabine. ADL=activities of daily living. \*Mean EORTC QLQ-C30 symptom score. †Calculated as 100/time in s to walk 20 m.](gr3){#fig3}

###### 

Baseline patient characteristics

                                   **Group A (n=115)**   **Group B (n=115)**   **Group C (n=115)**   **Group D (n=114)**   **Total (n=459)**
  -------------------------------- --------------------- --------------------- --------------------- --------------------- -------------------
  **Sex**                                                                                                                  
  Men                              73 (63%)              69 (60%)              68 (59%)              68 (60%)              278 (61%)
  Women                            42 (37%)              46 (40%)              47 (41%)              46 (40%)              181 (39%)
  **Age (years)**                                                                                                          
  Median                           75                    75                    73                    75                    74
  IQR                              71--78                71--78                69--78                70--79                70--78
  Range                            46--86                35--87                49--84                45--85                35--87
  **WHO performance status**                                                                                               
  0                                25 (22%)              23 (20%)              23 (20%)              27 (24%)              98 (21%)
  1                                58 (50%)              57 (50%)              58 (50%)              54 (47%)              227 (50%)
  2                                32 (28%)              35 (30%)              34 (30%)              33 (29%)              134 (29%)
  **Primary tumour site**                                                                                                  
  Rectum                           25 (22%)              30 (26%)              31 (27%)              34 (30%)              120 (26%)
  Colon                            90 (78%)              85 (74%)              84 (73%)              80 (70%)              339 (74%)
  Primary tumour not resected      39 (34%)              40 (35%)              40 (35%)              40 (35%)              159 (35%)
  **Metastatic sites**                                                                                                     
  No distant metastases            1 (1%)                2 (2%)                1 (1%)                1 (1%)                5 (1%)
  Non-liver metastases             31 (27%)              25 (22%)              30 (26%)              26 (23%)              112 (24%)
  Liver-only metastases            17 (15%)              14 (12%)              14 (12%)              22 (19%)              67 (15%)
  Liver+other metastases           66 (57%)              74 (64%)              70 (61%)              65 (57%)              275 (60%)
  **Reason for entering FOCUS2**                                                                                           
  Advanced age alone               35 (30%)              28 (24%)              37 (32%)              35 (31%)              135 (29%)
  Frailty/patient choice alone     37 (32%)              36 (31%)              35 (30%)              40 (35%)              148 (32%)
  Both age and frailty/choice      43 (37%)              51 (44%)              43 (37%)              39 (34%)              176 (38%)

Data are number (%), unless otherwise indicated.

###### 

Treatment received

                                                                                                                    **Group A**   **Group B**   **Group C**   **Group D**
  -------------------------------------------------- -------------------------------------------------------------- ------------- ------------- ------------- -------------
  Allocated first-line treatment                     FU                                                             OxFU          Cap           OxCap         
  Number allocated                                   115                                                            115           115           114           
  Number started treatment                           111                                                            107           111           111           
  Dose escalation at 6 weeks                                                                                                                                  
                                                     On study at 6 weeks                                            100           106           107           106
                                                     Dose escalated                                                 47 (47%)      36 (34%)      39 (36%)      32 (30%)
                                                     Eligible for escalation but not escalated                      31 (31%)      41 (39%)      30 (28%)      33 (31%)
                                                     Not escalated because of toxicity                              16 (16%)      23 (22%)      23 (21%)      38 (36%)
  Dose delivery during first 12 weeks of treatment                                                                                                            
                                                     Increased at 6 weeks and sustained                             20 (18%)      14 (13%)      11 (10%)      15 (14%)
                                                     Sustained starting dose                                        32 (29%)      32 (30%)      42 (38%)      40 (36%)
                                                     Further dose reduced or stopped                                57 (51%)      59 (55%)      54 (48%)      46 (41%)
                                                     Higher dose than intended[\*](#tbl2fn1){ref-type="table-fn"}   2 (2%)        2 (2%)        4 (4%)        10 (9%)

Data are number (%), unless otherwise indicated. FU=simplified LV5FU2 regimen of levofolinate, bolus fluorouracil, and 46-h infusion of fluorouracil, repeated every 2 weeks. OxFU=oxaliplatin plus FU. Cap=capecitabine. OxCap=oxaliplatin plus Cap.

These patients had a dose increase earlier than the protocol-specified week 6 escalation point.

###### 

Main outcome measures

                                                                                                                                                       **Individual groups**   **Factorial comparisons**                                                                                                                                          
  ----------------------- ------------------------------------------------------------ --------------------------------------------------------------- ----------------------- --------------------------- ----------------- ---------- ----------- ------------------- ----------------------------------------- ----------- ------------------- ----------------------------------------
  Number allocated        115                                                          115                                                             115                     114                         230               229        ..          230                 229                                       ..                              
  Survival and response                                                                                                                                                                                                                                                                                                                           
                          Number started treatment                                     111                                                             107                     111                         111               222        219         ..                  218                                       222         ..                  
                          RECIST response at week 12--14                                                                                                                                                                                                                                                                                          
                                                                                       Response rate: CR + PR (%)[\*](#tbl3fn1){ref-type="table-fn"}   12 (11%)                41 (38%)                    16 (14%)          36 (32%)   28 (13%)    77 (35%)            \<0·0001                                  53 (24%)    52 (23%)            0·83
                                                                                       Disease control: CR + PR + SD (%)                               51 (46%)                76 (71%)                    56 (50%)          72 (65%)   107 (48%)   148 (68%)           \<0·0001                                  127 (58%)   128 (58%)           0·90
                          Median PFS (months; IQR)[†](#tbl3fn2){ref-type="table-fn"}   3·5 (2·8--6·2)                                                  5·8(3·2--7·6)           5·2(2·8--6·7)               5·8(3·3--7·4)     ..         ..          ..                  ..                                        ..          ..                  
                                                                                       HR (95% CI)                                                     ..                      ..                          ..                ..         Reference   0·84 (0·69--1·01)   0·07                                      Reference   0·99 (0·82--1·20)   0·93
                          Median OS (months; IQR) [†](#tbl3fn2){ref-type="table-fn"}   10·1(5·1--17·3)                                                 10·7(5·7--17·2)         11·0(5·4--18·0)             12·4(5·8--18·0)   ..         ..          ..                  ..                                        ..          ..                  
                                                                                       HR (95% CI)                                                     ..                      ..                          ..                ..         Reference   0·99 (0·81--1·18)   0·91                                      Reference   0·96 (0·79--1·17)   0·71
                          Improved QoL at week 12--14                                                                                                                                                                                                                                                                                             
                                                                                       Complete QoL data                                               62                      62                          65                58         127         120                 ..                                        124         123                 ..
                                                                                       Improved global QoL (%)                                         37 (60%)                32 (52%)                    42 (65%)          27 (47%)   79 (62%)    59 (49%)            0·04                                      69 (56%)    69 (56%)            0·94
                          OTU score at 12 weeks                                                                                                                                                                                                                                                                                                   
                                                                                       Assessable for OTU                                              109                     107                         111               111        220         218                 ..                                        216         222                 
                                                                                       Good (%)                                                        38 (35%)                58 (54%)                    41 (37%)          45 (41%)   79 (36%)    103 (47%)           0·003[‡](#tbl3fn3){ref-type="table-fn"}   96 (44%)    86 (39%)            0·27[‡](#tbl3fn3){ref-type="table-fn"}
                                                                                       Intermediate (%)                                                37 (34%)                29 (27%)                    33 (30%)          41 (37%)   70 (32%)    70 (32%)            ..                                        66 (31%)    74 (33%)            ..
                                                                                       Poor (%)                                                        34 (31%)                20 (19%)                    37 (33%)          25 (23%)   71 (32%)    45 (21%)            ..                                        54 (25%)    62 (30%)            ..

FU=simplified LV5FU2 regimen of levofolinate, bolus fluorouracil, and 46-h infusion of fluorouracil, repeated every 2 weeks. OxFU=oxaliplatin plus FU. Cap=capecitabine. OxCap=oxaliplatin plus Cap. RECIST=Response Evaluation Criteria In Solid Tumors. CR=complete response. PR=partial response. SD=stable disease. PFS=progression-free survival. OS=overall survival. QoL=quality of life. OTU=overall treatment utility.

Interaction test: *Z*=−1·18, p=0·238.

Interaction tests done for time-to-event endpoints ([figure 2](#fig2){ref-type="fig"}) and OTU score.

χ^2^ test for trend.

###### 

Toxic effects, weeks 1--12

                     **Group A (FU; N=109)**   **Group B (OxFU; N=109)**   **Group C (Cap; N=112)**   **Group D (OxCap; N=110)**   **Factorial comparisons**                                         
  ------------------ ------------------------- --------------------------- -------------------------- ---------------------------- --------------------------- ---------- -------------------------- ----------
  **Any toxicity**                                                                                                                                                                                   
  Grade ≥2           84 (77%)                  81 (74%)                    86 (77%)                   94 (86%)                     170 (77%) *vs* 175 (80%)    0·45       165 (76%) *vs* 180 (81%)   0·17
  Grade ≥3           29 (27%)                  36 (33%)                    41 (37%)                   47 (43%)                     70 (32%) *vs* 83 (38%)      0·17       65 (30%) *vs* 88 (40%)     0·03
  **Nausea**                                                                                                                                                                                         
  Grade ≥2           8 (7%)                    17 (16%)                    15 (13%)                   27 (25%)                     23 (10%) *vs* 44 (44%)      \<0·0001   25 (12%) *vs* 42 (19%)     0·03
  Grade ≥3           1 (1%)                    2 (2%)                      6 (5%)                     5 (5%)                       7 (3%) *vs* 7 (3%)          0·99       3 (1%) *vs* 11 (5%)        0·03
  **Vomiting**                                                                                                                                                                                       
  Grade ≥2           5 (5%)                    13 (12%)                    12 (11%)                   21 (19%)                     17 (8%) *vs* 34 (16%)       0·01       18 (8%) *vs* 33 (15%)      0·03
  Grade ≥3           1 (1%)                    2 (2%)                      3 (3%)                     3 (3%)                       4 (2%) *vs* 5 (2%)          0·73       3 (1%) *vs* 6 (3%)         0·33
  **Anorexia**                                                                                                                                                                                       
  Grade ≥2           12 (11%)                  15 (14%)                    19 (17%)                   26 (24%)                     31 (14%) *vs* 41 (19%)      0·18       27 (12%) *vs* 45 (20%)     0·03
  Grade ≥3           3 (3%)                    3 (3%)                      6 (5%)                     4 (4%)                       9 (4%) *vs* 7 (3%)          0·62       6 (3%) *vs* 10 (5%)        0·33
  **Stomatitis**                                                                                                                                                                                     
  Grade ≥2           12 (11%)                  13 (12%)                    6 (5%)                     12 (11%)                     18 (8%) *vs* 25 (11%)       0·25       25 (12%) *vs* 18 (8%)      0·24
  Grade ≥3           2 (2%)                    3 (3%)                      1 (1%)                     2 (2%)                       3 (1%) *vs* 5 (2%)          0·47       5 (2%) *vs* 3 (1%)         0·46
  **Diarrhoea**                                                                                                                                                                                      
  Grade ≥2           20 (18%)                  21 (19%)                    23 (21%)                   38 (35%)                     43 (20%) *vs* 59 (27%)      0·06       41 (19%) *vs* 61 (28%)     0·03
  Grade ≥3           5 (5%)                    7 (6%)                      10 (9%)                    20 (18%)                     15 (7%) *vs* 27 (12%)       0·05       12 (6%) *vs* 30 (14%)      0·003
  **Lethargy**                                                                                                                                                                                       
  Grade ≥2           41 (38%)                  46 (42%)                    40 (36%)                   47 (43%)                     81 (37%) *vs* 93 (43%)      0·21       89 (40%) *vs* 87 (39%)     0·88
  Grade ≥3           8 (7%)                    10 (9%)                     15 (13%)                   16 (15%)                     23 (10%) *vs* 26 (12%)      0·63       18 (8%) *vs* 31 (14%)      0·06
  **Pain**                                                                                                                                                                                           
  Grade ≥2           17 (16%)                  18 (17%)                    24 (21%)                   20 (18%)                     41 (19%) *vs* 38 (17%)      0·74       35 (16%) *vs* 44 (20%)     0·30
  Grade ≥3           9 (8%)                    5 (5%)                      11 (10%)                   6 (6%)                       20 (9%) *vs* 11 (5%)        0·10       14 (6%) *vs* 17 (8%)       0·61
  **Neurosensory**                                                                                                                                                                                   
  Grade ≥2           2 (2%)                    10 (9%)                     4 (4%)                     15 (14%)                     6 (3%) *vs* 25 (11%)        0·0005     12 (6%) *vs* 19 (9%)       0·21
  Grade ≥3           0 (0%)                    1 (1%)                      0 (0%)                     4 (4%)                       0 (0%) *vs* 5 (2%)          0·02       1 (1%) *vs* 4 (2%)         0·18
  **HFS**                                                                                                                                                                                            
  Grade ≥2           1 (1%)                    2 (2%)                      24 (21%)                   13 (12%)                     25 (11%) *vs* 15 (7%)       0·10       3 (1%) *vs* 37 (17%)       \<0·0001
  Grade ≥3           0 (0%)                    0 (0%)                      11 (10%)                   2 (2%)                       11 (5%) *vs* 2 (1%)         0·01       0 (0%) *vs* 13 (6%)        0·0001
  **Platelets**                                                                                                                                                                                      
  Grade ≥2           0 (0%)                    2 (2%)                      1 (1%)                     2 (2%)                       1 (0·5%) *vs* 4 (2%)        0·17       2 (1%) *vs* 3 (1%)         0·67
  Grade ≥3           0 (0%)                    1 (1%)                      1 (1%)                     1 (1%)                       1 (0·5%) *vs* 2 (1%)        0·56       1 (0·5%) *vs* 2 (1%)       0·57
  **Anaemia**                                                                                                                                                                                        
  Grade ≥2           20 (18%)                  21 (19%)                    14 (13%)                   18 (16%)                     34 (15%) *vs* 39 (18%)      0·49       41 (19%) *vs* 32 (14%)     0·22
  Grade ≥3           3 (3%)                    3 (3%)                      1 (1%)                     2 (2%)                       4 (2%) *vs* 5 (2%)          0·73       6 (3%) *vs* 3 (1%)         0·30
  **Neutropenia**                                                                                                                                                                                    
  Grade ≥2           6 (6%)                    11 (10%)                    3 (3%)                     10 (9%)                      9 (4%) *vs* 21 (10%)        0·02       17 (8%) *vs* 13 (6%)       0·42
  Grade ≥3           3 (3%)                    6 (6%)                      2 (2%)                     2 (2%)                       5 (2%) *vs* 8 (4%)          0·39       9 (4%) *vs* 4 (2%)         0·15

Tests for interaction between the two treatment factors showed no evidence of an interaction (data not shown). FU=simplified LV5FU2 regimen of levofolinate, bolus fluorouracil, and 46-h infusion of fluorouracil, repeated every 2 weeks. OxFU=oxaliplatin plus FU. Cap=capecitabine. OxCap=oxaliplatin plus Cap. HFS=hand-foot syndrome.

###### 

Factors associated with OTU outcome (multivariate analysis)

                                   **Odds of a worse outcome (95% CI)**                   Z **value**   **p value**
  -------------------------------- ------------------------------------------------------ ------------- -------------
  Overall baseline symptom score   1·32[\*](#tbl5fn1){ref-type="table-fn"} (1·14--1·52)   3·79          \<0·0001
  Additional oxaliplatin           0·57 (0·39--0·82)                                      −2·98         0·003
  Liver with other metastases      1·51 (1·05--2·19)                                      2·22          0·026
  WHO performance status           1·28 (0·96--1·70)                                      1·70          0·090
  Age                              1·00 (0·98--1·02)                                      0·14          0·887

Interaction between the two treatment factors was assessed (*Z*=−1·26, p=0·209). OTU=overall treatment utility.

This odds ratio relates to a 10-point change in the overall symptom score.

###### Research in context

**Systematic review**

Previous publications and international meeting abstracts were searched with Ovid Medline and American Society of Clinical Oncology databases to find previous reports of palliative chemotherapy in elderly and frail patients with advanced colorectal cancer. Until now, the major reports of survival data for elderly patients receiving palliative chemotherapy have come from subgroup analyses of older patients participating in standard full-dose trials,[@bib4] or from trials of full-dose chemotherapy in selected fit elderly patients.[@bib24] These analyses show that elderly patients selected for full-dose treatments achieve survival times similar to younger patients on the same treatments; however, they represent only a small and highly selected proportion of the elderly cancer population.

**Interpretation**

FOCUS2 adds to the totality of evidence because it is the first large randomised trial in colorectal cancer to have been designed specifically for frail elderly patients and to relate objective baseline measures of geriatric fitness with patient-related outcomes of chemotherapy. Survival, at a median of 11 months, is noticeably shorter than in contemporaneous standard trials. For example, during overlapping recruitment periods two other MRC trials, FOCUS and COIN, were running at many of the same centres as FOCUS2, accruing patients with a median age of 63 years, more than 90% of whom had WHO performance status 0--1, with median survival of 14--17 months.[@bib10; @bib25; @bib26] Meanwhile, in France, a selective trial using more intensive therapy achieved median survival of more than 20 months.[@bib27] However, a meta-analysis of 6286 patients in nine trials, including FOCUS and the French trial, shows that frailty is a dominant negative prognostic factor, with median survival of only 8·5 months in the subpopulation with WHO performance stats of 2.[@bib9] This finding is entirely consistent with the survival recorded in FOCUS2, in which 134 of 459 (29%) patients were of performance status 2, and 324 of 459 (71%) were regarded as too frail to receive standard therapy ([table 1](#tbl1){ref-type="table"}).

[^1]: FOCUS2 Investigators listed at end of paper
